Recherche
Radiobiology for Targeted and Personalized Radiotherapy : Jean-Pierre POUGET & David AZRIA

Liste des Publications

Belkacemi Y, Debbi K, Besnard C, Grellier N, Fonteneau G, Colson-Durand L, Lerouge D, Durdux C, Campana F, Pons P, Flandin I, Pasquier D, de Crevoisier R, Wachter T, Thureau S, Conzague-Casabianca L, Petit A, Supiot S, Azria D [The morbidity and mortality review meetings in radiotherapy departments: Procedure, implementation and prospects of the "Proust" French national project]. Cancer Radiother. 2023;27(6-7):474-479. doi:10.1016/j.canrad.2023.06.018

Marguerit A, Azria D, Riou O, Demontoy S, Thezenas S, Boisselier P [Stereotactic Body Radiation Therapy for less than 3cm (stage I) and 5cm (stage II) inoperable lung tumors: 10 years experience of Montpellier Cancer Institute]. Cancer Radiother. 2023;27(5):387-397. doi:10.1016/j.canrad.2023.05.002

Bourgier C, Boisbouvier S, Bayart É, Chamois J, Clavère P, Corbin S, De Oliveira A, Hannoun-Lévi J-M, Hasbini A, Geffroy-Hulot C, Le Tallec P, Monpetit É, Santini J-J [Radiation therapists shortage in France: Organizational consequences and difficulties in deploying new missions and/or tasks delegation]. Cancer Radiother. 2023;27(6-7):577-582. doi:10.1016/j.canrad.2023.07.007

Hanslik N, Bourgier C, Thezenas S, Firmin N, Riou O, Azria D, Llacer-Moscardo C [Predictive factors assessment of pathological response to neoadjuvant radiotherapy of soft tissue sarcomas]. Cancer Radiother. 2023-10-07. doi:10.1016/j.canrad.2023.02.003

Legouté F, Lesueur P, El Kabbaj O, Ghannam Y, Michalet M, Monpetit E, Azria D, Giraud P, Calais G, Pointreau Y, Ollivier L [French careers in oncology radiotherapy: Crossing views]. Cancer Radiother. 2023;27(1):75-79. doi:10.1016/j.canrad.2022.07.016

Bollet M, Racadot S, Rivera S, Arnaud A, Bourgier C [Breast cancer radiation therapy: Current questions in 2023]. Cancer Radiother. 2023;27(6-7):524-530. doi:10.1016/j.canrad.2023.07.005

Bruneaux E, Iborra F, Trouche-Sabatier S, Foucan A, Gras-Aygon C, Poinas G, Azria D, Trétarre B [Bladder tumors in the Hérault department: Results of the Hérault tumor registry registration from1987 to 2019]. Prog Urol. 2023-08-28. doi:10.1016/j.purol.2023.08.015

Sargos P, Le Guevelou J, Khalifa J, Albiges L, Azria D, de Crevoisier R, Supiot S, Créhange G, Roubaud G, Chapet O, Pasquier D, Blanchard P, Latorzeff I The role of radiation therapy for de novo metastatic bladder and renal cancers. Cancer Radiother. 2023-06-05. doi:10.1016/j.canrad.2023.02.004

Aristei C, Kaidar-Person O, Boersma L, Leonardi M, Offersen B, Franco P, Arenas M, Bourgier C, Pfeffer R, Kouloulias V, Bölükba?? Y, Meattini I, Coles C, Luis A, Masiello V, Palumbo I, Morganti A, Perrucci E, Tombolini V, Krengli M, Marazzi F, Trigo L, Borghesi S, Ciabattoni A, Rato?a I, Valentini V, Poortmans P The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer. Crit Rev Oncol Hematol. 2023;187. doi:10.1016/j.critrevonc.2023.104035

Danieli R, Pistone D, Tranel J, Botta F, Uribe?Munoz C, Raspanti D, Salvat F, Wilderman S, Bardiès M, Amato E, Dewaraja Y, Cremonesi M Technical note: Impact of dose voxel kernel (DVK) values on dosimetry estimates in 177 Lu and 90 Y radiopharmaceutical therapy (RPT) applications. Medical Physics. 2023-09-15. doi:10.1002/mp.16729

Bordeau K, Michalet M, Keskes A, Valdenaire S, Debuire P, Cantaloube M, Cabaillé M, Jacot W, Draghici R, Demontoy S, Quantin X, Ychou M, Assenat E, Mazard T, Gauthier L, Dupuy M, Guiu B, Bourgier C, Fenoglietto P, Azria D, Riou O Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study. J Clin Med. 2023;12(3):1183. doi:10.3390/jcm12031183

Prunaretty J, Mir N, Tilhac A, Gouillou M, Azria D, Fenoglietto P, Bourgier C Robustness of Breast Margins with Volumetric Modulated Arc Therapy without a Six-Degrees-of-Freedom Couch: A Dosimetric Evaluation. J Clin Med. 2023;12(3):862. doi:10.3390/jcm12030862

Pouget J-P, Chan T, Galluzzi L, Constanzo J Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors. Trends Cancer. 2023;9(11):968-981. doi:10.1016/j.trecan.2023.07.014

Gueiderikh A, Sarrade T, Kirova Y, Auzac G, Martin A, Everhard S, Meillan N, Benyoucef A, Lacornerie T, Pasquier D, Racadot S, Moignier A, Paris F, André F, Deutsch E, Duchemann B, Allodji R, Rivera S Radiation-induced lung injury after breast cancer treatment: incidence in the CANTO-RT cohort and associated clinical and dosimetric risk factors. Front Oncol. 2023;13. doi:10.3389/fonc.2023.1199043

Bardiès M Quality assurance in clinical dosimetry. Hell J Nucl Med. 2023;26 Suppl.

Kayal G, Barbosa N, Calderón Marín C, Ferrer L, Fragoso-Negrín J-A, Grosev D, Gupta S, Hidayati N, Moalosi T, Poli G, Thakral P, Tsapaki V, Vauclin S, Vergara-Gil A, Knoll P, Hobbs R, Bardiès M Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study. J Nucl Med. 2023-10-26. doi:10.2967/jnumed.122.265340

Cusumano C, Deshayes E, Guiu B, De Meeus G, Carrère S, Bouillin A, Ilonca D, Éberlé M, Guillemard S, Fersing C, Sgarbura O, Quénet F Prevention of post-hepatectomy liver failure after major resection of colorectal liver metastases: is hepato-biliary scintigraphy the optimal tool?. Ann Transl Med. 2023;11(5):202-202. doi:10.21037/atm-22-3665

Taprogge J, Vergara-Gil A, Leek F, Abreu C, Vávrová L, Carnegie-Peake L, Schumann S, Eberlein U, Lassmann M, Schurrat T, Luster M, Verburg F, Vallot D, Vija L, Newbold K, Bardiès M, Flux G Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project. Eur J Nucl Med Mol Imaging. 2023;50(11):3225-3234. doi:10.1007/s00259-023-06295-0

Deshayes E, Fersing C, Thibault C, Roumiguie M, Pourquier P, Houédé N Innovation in Radionuclide Therapy for the Treatment of Prostate Cancers: Radiochemical Perspective and Recent Therapeutic Practices. Cancers. 2023;15(12):3133. doi:10.3390/cancers15123133

Prunaretty J, Debuire P, Cirella D, Eustache P, Riou O, Azria D, Fenoglietto P Implementation of the Calypso system: a commissioning experience. Rep Pract Oncol Radiother. 2023;28(2):304-307. doi:10.5603/RPOR.a2023.0029

Constanzo J, Bouden Y, Godry L, Kotzki P-O, Deshayes E, Pouget J-P Immunomodulatory effects of targeted radionuclide therapy. Int Rev Cell Mol Biol. 2023;378. doi:10.1016/bs.ircmb.2023.02.001

Galvez T, Berkane I, Eberlé M-C, Flori N, Guillemard S, Ilonca A, Santoro L, Kotzki P-O, Senesse P, Deshayes E Identification of 18F-FDG PET/CT Parameters Associated with Weight Loss in Patients with Esophageal Cancer. Nutrients. 2023;15(13):3042. doi:10.3390/nu15133042

Jandu H, Veal C, Fachal L, Luccarini C, Aguado-Barrera M, Altabas M, Azria D, Baten A, Bultijnck R, Colciago R, Farcy-Jacquet M-P, Chang-Claude J, Choudhury A, Dunning A, Elliott R, Green S, Gutiérrez-Enríquez S, Herskind C, Lambrecht M, Monten C, Rancati T, Reyes V, Rosenstein B, De Ruysscher D, Carmen De Santis M, Seibold P, Sperk E, Veldwijk M, Paul Symonds R, Stobart H, Taboada-Valladares B, Vega A, Veldeman L, Webb A, Weltens C, West C, Rattay T, Talbot C Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer. Radiother Oncol. 2023;187. doi:10.1016/j.radonc.2023.109806

Garcia-Prada C, Carmes L, Atis S, Parach A, Bertolet A, Jarlier M, Poty S, Garcia D, Shin W-G, Schuemann J, Tillement O, Lux F, Constanzo J, Pouget J-P Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy. J Nucl Med. 2023-10-19. doi:10.2967/jnumed.123.265418

Mangeat T, Gracia M, Pichard A, Poty S, Martineau P, Robert B, Deshayes E Fc-engineered monoclonal antibodies to reduce off-target liver uptake. EJNMMI Res. 2023;13(1):81. doi:10.1186/s13550-023-01030-0



© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés